Invivoscribe Begins Commercial Shipments of PrepQuant™ Systems, Enabling High-Sensitivity Sample Preparation for MRD Testing

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Invivoscribe Begins Commercial Shipments of PrepQuant™ Systems, Enabling High-Sensitivity Sample Preparation for MRD TestingAuthor of the article:New automated platform is designed to improve the quality, efficiency, and consistency of DNA extraction and concentration from large-volume blood and plasma samples, supporting downstream assays capable of detecting disease-associated signals at MRD sensitivity levels.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountSAN DIEGO — Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced that commercial shipments of the PrepQuant™ System have begun in North America. First unveiled at the American Association for Cancer Research Annual Meeting in April 2026, PrepQuant is now being delivered to customers, marking the platform’s progression from development and validation into commercial deployment.The commercial milestone extends Invivoscribe’s capabilities into laboratory instrumentation and addresses a critical bottleneck in highly sensitive molecular testing: efficiently recovering, concentrating, and quantifying DNA from larger blood and plasma inputs. PrepQuant is assay agnostic, designed to produce concentrated genomic DNA and cell-free DNA (cfDNA) suitable for a full range of downstream molecular workflows, including MRD assays intended to detect very low levels of residual disease.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againMRD Sensitivity Starts Before the AssayAs MRD testing moves toward greater sensitivity, sample preparation becomes more critical to recovering rare disease-associated molecules. Larger inputs can increase the amount of DNA available for analysis, but they also create challenges involving extraction efficiency, DNA recovery, concentration, processing time, and consistency.Many laboratories currently rely on separate protocols and instruments for extraction, concentration, and quantification. Each transfer can add hands-on time and create another opportunity for variability or error, while fragmented workflows can limit throughput as testing volumes grow. The concept for PrepQuant was informed by operational challenges observed across LabPMM, Invivoscribe’s global network of clinical laboratories.You cannot detect what you do not recover.An Integrated Platform for Larger Sample InputsPrepQuant integrates nucleic acid extraction, concentration, and quantification into one automated platform. By replacing multiple instruments and protocols with a standardized workflow, the system is designed to reduce hands-on labor, sample handling, variability, operating costs, and bench-space requirements.The assay agnostic system generates highly concentrated genomic DNA and cfDNA for next-generation sequencing, capillary electrophoresis, quantitative PCR, and digital PCR assays. It is designed and validated for blood, plasma, and bone marrow samples, with additional sample types under development. Its broad compatibility establishes a platform for future PrepQuant kits and applications.A Platform Opportunity Across the MRD Testing WorkflowPrepQuant extends Invivoscribe’s standardization strategy upstream of molecular analysis, complementing the company’s MRD assays, bioinformatics, and global clinical testing capabilities. Automation and standardization can make sophisticated workflows more practical as testing volumes grow and can support greater consistency across research, reference, and clinical laboratories.“As precision oncology advances and MRD testing becomes mainstream, laboratories cannot focus on analytical sensitivity alone,” said Jeff Miller, CEO and CSO of Invivoscribe. “The ability to generate reliable molecular data begins upstream, with how the sample is processed and how effectively the available nucleic acid is recovered and consistently quantified. PrepQuant reflects our broader view that standardization across the entire testing continuum will be increasingly important as molecular MRD testing becomes integral both to monitoring disease and evaluating the effectiveness of new therapies.”Initial PrepQuant Systems are now being delivered to customers in North America, with European availability early in 2027. Invivoscribe is currently developing additional PrepQuant kits to expand the platform’s capabilities to address the entire range of molecular testing workflows.Laboratories interested in purchasing PrepQuant, requesting a quotation, or learning more may contact Invivoscribe at inquiry@invivoscribe.com.Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For more than 30 years, Invivoscribe has advanced precision medicine by providing high-quality standardized reagents, assays, bioinformatics tools, and clinical testing services, while supporting pharmaceutical partners through clinical trials, companion diagnostic development, and global regulatory expertise. With the launch of the PrepQuant System, the Invivoscribe ecosystem now includes instrumentation, extending the company’s standardization efforts into the critical pre-analytical workflows that support accurate and reproducible molecular testing. For more information, visit www.invivoscribe.com, contact inquiry@invivoscribe.com, or follow Invivoscribe on LinkedIn.View source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.